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ABSTRACT
Objective: CHA2DS2-VASc score, left atrial (LA) size
and atrial fibrillation (AF) have individually been
associated with stroke risk. Our aim was to investigate
the predictive ability of combinations of these factors
for the odds of incident stroke in a population-based
cohort study.
Methods: We followed 2844 participants from the
Tromsø Study from 1994 to 2012. Information on LA
size and CHA2DS2-VASc score (age, sex, congestive
heart failure, hypertension, vascular disease, stroke and
diabetes) were obtained at baseline. AF status was
recorded from medical records. The outcome measure
was all strokes. The association between covariates and
stroke was investigated by means of multivariate
logistic regression analysis.
Results: A total of 325 participants (45% women, mean
age at baseline 59.3 years) had a stroke. Incidence rates
for stroke were 6.4 in women and 8.4 in men per 1000
person-years. Participants with CHA2DS2-VASc ≥1 and
LA size <2.8 had ∼4 times (95% CI 2.6 to 5.3) increased
odds of stroke, whereas participants with CHA2DS2-VASc
≥1 and LA size ≥2.8 had ∼9 times (95% CI 5.3 to 16.4)
increased odds of stroke, compared with participants
with CHA2DS2-VASc score 0, irrespective of AF status.
Adjustment for significant covariates had minimal impact
on the OR estimates.
Conclusions: Combining CHA2DS2-VASc score ≥1 and
enlarged LA size identified participants with high odds of
stroke regardless of AF status.
INTRODUCTION
Ischaemic stroke is the most devastating com-
plication resulting from atrial ﬁbrillation
(AF), and AF-related strokes are more
severe.1
The CHA2DS2-VASc score estimates stroke
risk in non-anticoagulated patients with AF.2 It
combines common risk factors for stroke such
as congestive heart failure, hypertension, age,
diabetes, previous stroke/transient ischaemic
attack (TIA), vascular disease and sex. A previ-
ous prospective study investigated the
CHA2DS2-VASc score among non-AF high-risk
patients, and concluded that the score strongly
predicts new onset of ischaemic stroke, myo-
cardial infarction, cardiovascular death and
combined cardiovascular end points, includ-
ing congestive heart failure.3 A study with a
mean follow-up of 1.1 years using continuous
monitoring in stroke-free patients without pre-
viously diagnosed AF and elevated stroke risk
found that 30% of the patients had AF.4
Left atrial (LA) size is associated with
increased cardiovascular disease risk, includ-
ing AF and stroke.5–9
How to combine these factors to identify
stroke risk has been unclear, as most of the
studies have assessed the association with
stroke risk for each factor separately. Our aim
was to investigate the predictive ability of com-
binations of CHA2DS2-VASc score, LA size and
AF status for odds of incident stroke in the
population-based Tromsø Study with 18 years
of follow-up.
KEY QUESTIONS
What is already known about this subject?
▸ CHA2DS2-VASc score, left atrial size (LA) and
atrial fibrillation (AF) have previously been
shown to be associated with stroke risk for each
factor separately.
What does this study add?
▸ This study provides long-term results for the
association between combinations of
CHA2DS2-VASc score, LA and AF with stroke
risk in a large general cohort. Participants with
higher CHA2DS2-VASc score and enlarged LA
size had approximately nine times increased
odds of stroke irrespective of AF status.
How might this impact on clinical practice?
▸ Our study may indicate that Holter monitoring in
people with no known AF, but with increased
risk of stroke due to high CHA2DS2-VASc score
and risk of AF, may be important. In addition,
the risk factors that increase the CHA2DS2-VASc
score as well as AF risk factors should be moni-
tored and managed properly.
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METHODS
Study population
The Tromsø Study is a prospective cohort study con-
ducted in the municipality of Tromsø, Norway.10 It was
initiated in 1974 with the emphasis on epidemiology
and surveillance of modiﬁable risk factors for cardiovas-
cular diseases. In the fourth survey (Tromsø 4) in 1994–
1995, all inhabitants 25 years or older were invited and
27 158 persons (77% of the eligible population) partici-
pated. Among them, all individuals aged 55–74 years
and 5–10% random samples of the other age groups
(aged 25–54 and 75–84 years) were invited for a second
visit, which included extensive examinations. The selec-
tion of participants eligible for the second visit was
based on economical and scientiﬁc reasons and was per-
formed before they attended the ﬁrst visit. The 6902
individuals who attended the second visit were randomly
allocated based on simple randomisation with computer-
generated random numbers to one of two lines of exam-
ination, one of which comprised echocardiographic
examination.11 The attendance rate was 88%.12 Figure 1
shows that after exclusions, 2844 participants were
included. All participants have given informed consent,
the Tromsø Study complies with the Declaration of
Helsinki and has been approved by the Regional
Committee for Medical and Health Research Ethics, the
Data Inspectorate and the Norwegian Directorate of
Health.
Baseline characteristics
Questionnaire data were used to deﬁne predictor variables
on diabetes (yes/no), antihypertensive medication use
(current/previous/never), smoking (current/previous/
never), palpitations (yes/no) and prevalent coronary heart
disease (CHD) (yes/no). Prevalent CHD was deﬁned as
self-reported previous myocardial infarction. Body mass
index (BMI) was calculated as weight/height2 (kg/m2)
and body surface area (BSA) was calculated by Du Bois
formula (BSA=(Weight0.425×Height0.725)×0.007184). Blood
pressure and heart rate were recorded three times with 1
min intervals after 2 min resting, by trained technicians
using an automatic device (Dina map Vital Signs Monitor
1846, Criticon). For the analysis, the mean from the
second and third readings was used. Hypertension was
deﬁned as systolic blood pressure ≥140 mmHg or diastolic
blood pressure ≥90 mm Hg or current antihypertensive
medication use.
Plasma creatinine was analysed by a modiﬁed Jaffe
reaction, but since creatinine-based estimation of glom-
erular ﬁltration rate (GFR) is better validated for enzym-
atic creatinine measurements, 111 plasma samples from
the 1994/1995 survey were thawed and reanalysed with
an enzymatic method (Modular P/Roche). Values were
ﬁtted to a linear regression model, and recalibrated cre-
atinine values were calculated for all participants.
Estimated GFR was calculated according to the CKD-EPI
formula13 and renal failure was deﬁned as having GFR
<60 mL/min/1.73 m2. Non-fasting total cholesterol was
analysed by enzymatic methods with commercial kits
and serum high-density lipoprotein (HDL) cholesterol
was measured after the precipitation of lower-density
lipoprotein with heparin and manganese chloride. All
blood sample analyses were performed at the
Department of Clinical Chemistry, University Hospital of
North Norway.
We calculated CHA2DS2-VASc score, which aids in
identifying additional stroke risk factors for patients with
AF. To calculate the score, the variables used were age
(<65:0 for both sexes, 65–74: +1, ≥75: +2), sex (female
≥65: +1), history of congestive heart failure (+1), hyper-
tension (+1), stroke/TIA/thromboembolism (+2), vascu-
lar disease (+1) and diabetes mellitus (+1).14 15
Echocardiography
Echocardiographic examinations were performed on all
participants by two expert cardiologists using a
VingMED CFM 750 (VingMED Sound A/S, Horten,
Norway) with a combined 3.25 MHz mechanical and
2.5 MHz Doppler probe. The examinations were per-
formed using the standard apical and parasternal long-
axis and short-axis views. Standard two-dimensional
guided M-mode registrations of anteroposterior LA size,
internal dimensions of the left ventricle and wall thick-
ness of the septum and posterior wall were made from
leading edge to leading edge convention.16 In this study,
LA size was indexed by BSA. Heart failure was deﬁned as
left ventricular ejection fraction <0.5.
Atrial fibrillation
All participants were followed with respect to incident
clinical AF documented by an ECG before or until date
of stroke. The national personal identiﬁcation number
of participants was linked to the diagnosis registry at the
University Hospital of North Norway (outpatient clinic
included), using the following diagnostic codes: ICD-9
codes 427.0–427.99 and ICD-10 codes I47 and I48. In
addition, we performed manual text search for partici-
pants without an arrhythmia diagnosis but with a diagno-
sis of cerebrovascular or cardiovascular events. An
independent committee adjudicated all events. Types of
AF were categorised into paroxysmal (paroxysmal or
persistent), permanent or unclassiﬁed. We combined
paroxysmal and persistent AF because it was difﬁcult to
make absolute decisions about the correct type. All AF
types were merged in the multivariable analysis.
Participants with transient AF occurring only during an
acute myocardial infarction, in connection with cardiac
surgery, or in the last 7 days of life, were not classiﬁed as
having AF. The adjudication of AF is described in detail
previously.6 17
Reproducibility
A reproducibility study of the echocardiographic data
was performed in a subsample of 58 participants by 2
cardiologists. All participants were examined twice with
1-week interval by both observers. Data concerning the
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reproducibility of the echocardiography are given else-
where.12 This study shows that the validity of the echo-
cardiographic measurements is good due to the use of a
representative sample from a general population with a
large age-span and a high attendance rate. The reliabil-
ity of measurements from independently recorded
heartbeats is good, and the reliability is further strength-
ened by 83% of the examinations being performed by
one observer. There was no systematic measurement vari-
ability invalidating the data.
Classification of LA size
We indexed the LA size by BSA and categorised into two
groups as normal or moderately enlarged (<2.8 cm/m2)
and severely enlarged (≥2.8 cm/m2) left atria.
Classification of combined analytical groups
We combined CHA2DS2-VASc score, LA size and AF
together and made the following groups:
Group 1=CHA2DS2-VASc score=0;
Group 2=CHA2DS2-VASc score ≥1 and normal or mod-
erately enlarged LA (<2.8 cm/m2) and AF;
Group 3=CHA2DS2-VASc score ≥1 and normal or mod-
erately enlarged LA (<2.8 cm/m2) and no AF;
Group 4=CHA2DS2-VASc score ≥1 and severely enlarged
LA (≥2.8 cm/m2) and AF;
Group 5=CHA2DS2-VASc score ≥1 and severely enlarged
LA (≥2.8 cm/m2) and no AF.
End points
We followed all participants who attended Tromsø 4 for
incident cases of stroke, as described previously.18 With
the exclusion of subarachnoid haemorrhage, we com-
bined ischaemic stroke, haemorrhagic stroke and unclas-
siﬁed stroke as one common end point. The combined
stroke end point was preferred as the result for ischae-
mic stroke only and the combined end point were
similar, but with narrower CIs for combined stroke.
Figure 1 Study population, the Tromsø Study 1994–2012.
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Norway has a unique personal identiﬁcation system
that allows exact matching of population register data.
The identiﬁcation number of participants of the 1994–
1995 survey was linked to the diagnosis registry at the
University Hospital of North Norway (the outpatient
clinic included), the only hospital in this area, and to
the National Causes of Death Registry at Statistics
Norway. Cases of possible non-fatal and fatal stroke were
identiﬁed by a broad search for the following diagnosis
codes of cerebrovascular disease: International
Classiﬁcation of Diseases (ICD) 8 and 9 codes 430–438,
and ICD 10 codes I60–I69 (cerebrovascular diseases). In
addition, systematic manual and electronic text searches
were performed in the medical records for patients with
ICD 8 and 9 diagnosis codes 410–414 and 798–799, and
ICD 10 codes I20–I25 and R96, R98 and R99.
Adjudication of hospitalised and out-of-hospital events
was performed by an independent end point committee
based on data from hospital and out-of-hospital medical
records, autopsy records and death certiﬁcates. For the
computation of stroke incidence (excluding subarach-
noid haemorrhage), we followed 2844 participants
(ﬁgure 1) until the date of ﬁrst stroke or date of censor-
ing due to death, migration or end of follow-up at 31
December 2012, whichever came ﬁrst. Those who had
died or emigrated from Tromsø during follow-up were
identiﬁed through the Population Register of Norway.
Statistical analysis
We present the characteristics of the study population
with and without stroke as means and SDs for continu-
ous variables and proportions of group total for categor-
ical variables. Differences between groups were assessed
by t-test, χ2 test and Fisher’s exact test. To estimate ORs
for stroke, we used both age-adjusted and multivariable
logistic regression analysis adjusted for smoking, total/
HDL cholesterol ratio, BMI, GFR and palpitations. The
variables that were included in the ﬁnal multivariable
model were chosen based on known risk factors for
stroke or variables signiﬁcant in our univariable analysis.
We have chosen logistic and not Cox proportional
hazard regression analysis because the covariate AF is
taken from the end point registry without knowledge of
when the AF started, although both methods gave
similar results. We tested for interactions between LA
size and AF and sex, and the p values were 0.162 and
0.004, respectively. We calculated the c-statistic of the
model to predict its clinical usefulness for distinguishing
high-risk from low-risk participants. In addition, Net
Reclassiﬁcation Improvement (NRI) and Integrated
Discrimination Improvement (IDI) were calculated to
quantify improvement in model performance. A two-
sided p value of <0.05 was considered statistically signiﬁ-
cant. Statistical analysis was performed using STATA V.12
(Stata, College Station, Texas, USA). The NRI and IDI
were calculated with user written program by Liisa
Byberg.
RESULTS
Incident stroke was identiﬁed in 145 women (10.1%)
and 180 men (12.7%) (ﬁgure 1) during a mean
follow-up of 15.5 years (44 147 person-years). The inci-
dence rate (per 1000 person-years) of stroke was 6.4 in
women and 8.4 in men. Table 1 shows the baseline
characteristics for participants with and without stroke.
Participants who developed stroke were signiﬁcantly
older, had higher blood pressure, prevalence of CHD,
diabetes and used antihypertensive medication. They
also had higher BMI and total/HDL cholesterol ratio
(not statistically signiﬁcant in men) and renal failure
(not statistically signiﬁcant in women). There were no
signiﬁcant differences in smoking and palpitations.
Table 2 shows CHA2DS2-VASc score, LA size and AF
status, for participants with and without stroke.
Participants with stroke had increasing CHA2DS2-VASc
score, larger LA size and higher prevalence of AF (not
statistically signiﬁcant in men).
The incidence rate of stroke increased with increase
in CHA2DS2-VASc score for both sexes and the increase
with increasing score was much steeper in those with no
AF (see online supplementary table S1).
Table 3 shows the OR for stroke according to
CHA2DS2-VASc score, indexed LA size and AF. The
CHA2DS2-VASc and AF status were signiﬁcant predictors of
subsequent stroke. For AF, the increased risk was related to
the ﬁrst half of the follow-up period. Compared with parti-
cipants in the reference group (CHA2DS2-VASc=0), partici-
pants with CHA2DS2-VASc ≥1 and LA size <2.8 had ∼4
times (95% CI 2.6 to 5.3) increased odds of stroke, irre-
spectively of the presence of prevalent AF. Similarly, partici-
pants with CHA2DS2-VASc ≥1 and LA size ≥2.8 had ∼9
times (95% CI 5.3 to 16.4) times increased odds of stroke.
Those with CHA2DS2-VASc ≥1, LA size ≥2.8 and no AF
(group 5) had the highest odds, increasing from 12.1
(95% CI 6.3 to 23.2) to 12.5 (95% CI 6.4 to 24.3) after
adjustment for signiﬁcant covariates, but was not signiﬁ-
cantly greater than for those with AF. This conclusion was
unchanged when sex-speciﬁc analysis was conducted.
Including eight participants with AF in the terminal 7 days
of life, where three died from stroke, did not change our
results. Adding palpitations to the multivariable model
caused no changes in the point estimates. In addition to
CHA2DS2-VASc score and AF status, total/HDL cholesterol
ratio and low GFR were signiﬁcant risk factors. Men had
higher overall risk, but there was no sex interaction for the
risk factors. The model with CHA2DS2-VASc, LA size
groups and AF status and the other predictor variables
together (Model 2) gave better prediction than a model
with the predeﬁned groups only (Model 1) (Harrell’s
c=0.68 vs 0.66, p=0.003). The unadjusted ORs for stroke
according to the three different components of the com-
bined analytical groups group are given in online
supplementary table S2.
For the full model, NRI was 5.8%, p=0.01 and IDI was
0.7%, p=0.001. Adding only AF status and LA size to
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Table 1 Unadjusted baseline characteristics of women and men by future stroke status
Women Men
Baseline characteristics
Stroke
(n=145)
No stroke
(n=1286) p Value
Stroke
(n=180)
No stroke
(n=1233) p Value
Age (years) 66.7 (6.3) 59.1 (10.6) <0.0001 63.6 (7.1) 58.0 (10.6) <0.0001
Systolic blood pressure (mm Hg) 157.1 (26.9) 142.0 (23.0) <0.0001 153.0 (22.4) 142.9 (19.3) <0.0001
Diastolic blood pressure
(mm Hg)
86.6 (15.2) 80.7 (12.3) <0.0001 88.7 (13.1) 84.1 (11.4) <0.0001
Body mass index (kg/m2) 27.2 (4.7) 25.8 (4.4) 0.0003 26.5 (3.4) 26.1 (3.3) 0.1054
Total cholesterol (mmol/L) 7.20 (1.10) 6.82 (1.33) 0.0010 6.62 (1.18) 6.52 (1.21) 0.2924
HDL cholesterol (mmol/L) 1.61 (0.41) 1.69 (0.42) 0.0367 1.37 (0.40) 1.41 (0.39) 0.3038
Total/HDL cholesterol ratio 4.72 (1.43) 4.28 (1.40) 0.0003 5.17 (1.73) 4.96 (1.58) 0.0893
Smoking, % (n) 0.736 0.995
No smoking 46.2 (67) 45.7 (587) 20.0 (36) 20.0 (247)
Previous smoking 22.1 (32) 24.8 (319) 45.6 (82) 45.2 (557)
Current smoking 31.7 (46) 29.6 (380) 34.4 (62) 34.8 (429)
Hypertension, % (n) 73.8 (107) 52.5 (675) <0.0001 77.8 (140) 56.5 (696) <0.0001
Current antihypertensive
treatment, % (n)
20.8 (30) 11.5 (148) <0.0001 19.1 (34) 10.5 (129) <0.0001
Coronary heart disease, % (n) 5.6 (8) 2.6 (33) 0.06 15.7 (28) 6.5 (80) <0.0001
Heart failure, % (n) 0 (0) 0.4 (4) 6.5 (9) 1.3 (13) <0.0001
Palpitations, % (n) 37.6 (41) 30.2 (330) 0.110 18.5 (29) 18.7 (213) 0.953
Diabetes, % (n) 6.0 (8) 1.9 (24) 0.011 6.2 (11) 2.1 (26) 0.002
HbA1c (%) 5.6 (1.0) 5.4 (0.7) 0.0060 5.6 (0.9) 5.4 (0.6) <0.0001
GFR <60, % (n) 2.8 (4) 1.5 (19) 0.280 3.4 (6) 0.9 (11) 0.014
Mean (SD) or percentage (number of participants). The Tromsø Study 1994–1995. GFR, glomerular filtration rate; HDL, high-density
lipoprotein.
Table 2 Unadjusted CHA2DS2-VASc score, indexed left atrial size and atrial fibrillation status in women and men according
to future stroke status
Women Men
Stroke
(n=145)
No stroke
(n=1286) p Value
Stroke
(n=180)
No stroke
(n=1233) p Value
CHA2DS2-VASc score, % (n)
0 13.8 (20) 38.7 (497) <0.0001 10.6 (19) 34.1 (421) <0.0001
1 17.2 (25) 26.4 (340) 40.6 (73) 41.9 (517)
2 11.7 (17) 8.9 (115) 36.7 (66) 19.2 (237)
3 44.1 (64) 23.1 (297) 8.3 (15) 4.3 (53)
4 or more 13.1 (19) 2.9 (37) 3.9 (7) 0.4 (5)
LA size indexed by BSA (cm/m2)
<2.2 37.0 (50) 53.1 (658) <0.0001 54.1 (92) 63.6 (762) 0.014
2.2–2.79 47.4 (64) 42.3 (524) 41.8 (71) 34.8 (417)
≥2.8 15.6 (21) 4.7 (58) 4.1 (7) 1.7 (20)
Atrial fibrillation (AF)
AF, % (n) 26.9 (39) 12.5 (161) <0.0001 19.4 (35) 17.7 (218) 0.564
AF before or until up to date of stroke, % (n)
No AF 73.1 (106) 87.5 (1125) <0.0001 80.6 (145) 82.3 (1015) 0.329
Paroxysmal/persistent
AF
12.4 (18) 5.5 (71) 6.7 (12) 8.0 (99)
Permanent AF 14.5 (21) 6.6 (85) 12.8 (23) 9.0 (111)
Unclassified AF 0 0.4 (5) 0 0.7 (8)
AF after stroke, % (n)
No AF 81.1 (86) 84.8 (123)
Paroxysmal/persistent
AF
10.4 (11) 6.9 (10)
Permanent AF 8.5 (9) 7.6 (11)
Unclassified AF 0 0.7 (1)
Percentage (number of participants). The Tromsø Study 1994–1995.
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CHA2DS2-VASc has an NRI and IDI of 2.6%, p=0.21 and
0.2%, p=0.08, respectively.
Among the participants with CHA2DS2-VASc score ≥1
without AF before stroke, 23% reported palpitations at
baseline. Palpitations were not an independent predictor
of stroke and the incidence was similar in those with and
without palpitations (14% vs 13%) in this group.
DISCUSSION
CHA2DS2-VASc score, LA size, AF status and stroke risk
We found that adding LA size to elevated
CHA2DS2-VASc score gave additional stratiﬁcation of
stroke risk irrespective of AF status. To the best of our
knowledge, this is a novel ﬁnding.
The highest stroke risk was among participants with
high CHA2DS2-VASc score and severely enlarged LA
size. Self-reported palpitations did not independently
predict stroke risk, despite an increased risk of AF17 with
enlarged LA size.6
Several studies have shown an association with stroke
for CHA2DS2-VASc score and LA size. A 5-year follow-up
study of high-risk patients found that CHA2DS2-VASc
score strongly predicted ischaemic stroke among non-AF
patients.3 A prospective study among patients with heart
failure found that CHA2DS2-VASc score was associated
with the risk of ischaemic stroke with or without AF.19
Another study on LA dimension and stroke risk in a
Chinese population without AF with long follow-up
found an association between increased LA size and inci-
dent stroke in women, but not in men.7 However, in the
Framingham Heart Study, LA enlargement was a signiﬁ-
cant predictor of stroke in men only after multivariable
adjustment also adjusted for AF.8 We did not conﬁrm
any sex interactions with LA size. We found a higher
incidence of stroke in men compared with women,
which is in line with previous ﬁndings from the Tromsø
Study.18
There is an ongoing discussion on how to manage
intermediate-risk AF patients with one additional risk
factor of the CHA2DS2-VASc score beyond sex.
20–22
Evidence from two large studies suggested that anticoa-
gulation should be considered in these patients and that
the risk factors carried various risk with age 65–74 years
associated with the highest stroke rate. Our study did
not have enough power to further elucidate this matter.
Incidence of stroke among AF patients
We found that the incidence of stroke was 23.3% among
those with ever-diagnosed AF. On the other hand,
among patients who had stroke, 22.8% had diagnosed
AF before the stroke and 12.9% had AF diagnosed after
stroke. This is similar to a cross-sectional study of
patients in nationwide Swedish health registers with a
5-year inclusion period. They found that 22.1% of
Table 3 OR (95% CI) for stroke according to CHA2DS2-VASc score, indexed left atrial size and atrial fibrillation combined:
the Tromsø Study 1994–2012
Model 1 Model 2
CHA2DS2-VASc and LA size
CHA2DS2-VASc=0, Group 1 (n=957) 1 (Ref.) 1 (Ref.)
CHA2DS2-VASc ≥1
LA size <2.8, Group 2 (n=1713) 3.9 (2.7 to 5.5) 3.7 (2.6 to 5.3)
LA size ≥2.8, Group 3 (n=96) 9.7 (5.6 to 16.7) 9.4 (5.3 to 16.4)
Atrial fibrillation (AF)*
No AF, Group 1 (n=2391) 1 (Ref.) 1 (Ref.)
Late AF, Group 2 (n=266) 1.0 (0.7 to 1.6) 1.0 (0.6 to 1.5)
Early AF, Group 3 (n=142) 2.8 (1.9 to 4.2) 2.6 (1.7 to 3.9)
Previous AF, Group 4 (n=45) 2.4 (1.2 to 5.0) 2.2 (1.1 to 4.5)
Combined analytical group
CHA2DS2-VASc=0, Group 1 (n=957) 1 (Ref.) 1 (Ref.)
CHA2DS2-VASc ≥1 and LA size <2.8
AF, Group 2 (n=331) 5.0 (3.3 to 7.7) 4.9 (3.1 to 7.6)
No AF, Group 3 (n=1382) 3.6 (2.5 to 5.1) 3.5 (2.4 to 5.0)
CHA2DS2-VASc ≥1 and LA size ≥2.8
AF, Group 4 (n=43) 7.1 (3.3 to 15.5) 6.3 (2.8 to 14.3)
No AF, Group 5 (n=53) 12.1 (6.3 to 23.2) 12.5 (6.4 to 24.3)
Smoking (no/yes) 1.1 (0.8 to 1.4)
Total/HDL cholesterol ratio 1.1 (1.1 to 1.2)
BMI (kg/m2) 1.1 (1.02 to 1.1)
GFR <60 mL/min/1.73 m² 2.6 (1.3 to 5.5)
Model 1: Unadjusted.
Model 2: Adjusted for smoking, Total/HDL cholesterol ratio, BMI, GFR.
*AF, any diagnosis of AF before or until up to date of stroke; early AF, AF diagnosed from 1994 to 2002; Late AF, AF diagnosed from 2003 to
2012; previous AF, AF at baseline.
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ischaemic stroke patients had previously diagnosed AF at
the time of stroke and 8.1% were diagnosed after the
stroke, leaving around 30% of patients who had stroke
with AF as likely contributing cause.23
High CHA2DS2-VASc score and undiagnosed AF
We found that even among those with no known AF prior
to stroke, the CHA2DS2-VASc score was a strong predictor
of stroke and about 13% developed AF after stroke. In a
cross-sectional study, the likelihood of AF among patients
with stroke was directly correlated to the CHA2DS2-VASc
score.23 We have identiﬁed a group of participants with
high risk of stroke and no AF, and we believe that Holter
monitoring might be valuable in the follow-up of these
individuals as they have an increased risk of AF. We
assume the increased stroke risk in participants without
AF probably was due to undiagnosed paroxysmal and/or
persistent AF. In addition, the risk factors that increase
the CHA2DS2-VASc score as well as AF risk factors should
be monitored and managed properly.
Strengths
The study was performed in a large population-based
cohort of both sexes, with a high attendance rate and a
long follow-up. Another strength was the thorough case
validation and search methods. The hospital discharge
list may be incomplete, and we found some people who
were not registered with an AF diagnosis, but where
ECG or medical texts documented AF. The reproducibil-
ity study of the echocardiographic data collection gave
coefﬁcients of variation similar to other studies and have
been presented in detail previously.12 There was no sys-
tematic measurement variability invalidating the data in
this reproducibility study.
Limitations
Stroke information was collected through linkage to the
hospital diagnosis registry and the National causes of
Death Register at Statistics Norway; this could have led
to underestimation of non-fatal strokes, if they were not
referred to hospital. Although a detailed search method
was used, there may still be individuals with undiagnosed
AF. Participants with asymptomatic or paroxysmal AF
often fail to get their arrhythmia documented. We
included only participants having hospital-diagnosed AF
before stroke, and any AF only recorded by the patient’s
general practitioner were missed. The Tromsø Study esti-
mated LA size by M-mode diameter measurement. As
LA size is best evaluated by estimation of volume, our
OR estimates are probably attenuated. The external val-
idity refers to a Caucasian population, and may not be
generalisable to other groups.
CONCLUSIONS
Our study concludes that a combination of
CHA2DS2-VASc score ≥1 and enlarged LA size is an
important risk factor for stroke irrespective of AF status.
Correction notice This paper has been updated since it published Online
First. In the methods section, references to CHA2DS2 have been updated to
CHA2DS2-VASc.
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